RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma

RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma

Abstract Background RORγt is a transcription factor that enables elaboration of Th17-associated cytokines (including IL-17 and IL-22) and is proposed as a pharmacological target for severe asthma. Methods IL-17 immunohistochemistry was performed in severe asthma bronchial biopsies (specificity confi...

Full description

Bibliographic Details
Main Authors: David Lamb, Dorothy De Sousa, Karsten Quast, Katrin Fundel-Clemens, Jonas S. Erjefält, Caroline Sandén, Hans Jürgen Hoffmann, Marc Kästle, Ramona Schmid, Kevin Menden, Denis Delic
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Respiratory Research
Subjects:
RORgt
IL-17
IL-22
Severe asthma
Inhibitor
Mouse model
Online Access:https://doi.org/10.1186/s12931-021-01743-7

Internet

https://doi.org/10.1186/s12931-021-01743-7

Similar Items